NCT05975983: An ongoing trial by InSilico Medicine Hong Kong Limited
This trial is ongoing. It must report results 10 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05975983 |
|---|---|
| Title | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 8, 2024 |
| Completion date | Feb. 28, 2026 |
| Required reporting date | Feb. 28, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |